Astellas Buys Asia Rights For Constipation Drug From Ironwood Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma says it has bought exclusive rights to develop and market linaclotide, a constipation drug, from U.S.-based Ironwood Pharmaceuticals for up to $75 million